Peptron, Inc. is a Korea-based company principally engaged in the development, manufacture and distribution of sustained-release medications. The Company mainly produces peptides as drug materials mainly for prostate cancer, hyperpituitarism, diabetes and neurodegenerative disorders. The Company also provides peptide synthesis services. The Company manufactures raw material medicines and some functional cosmetics. The Company distributes its products within domestic market and to overseas markets.

Employees

Sector

Biotechnology & Medical Research

Calendar

2025-04-06 - Q4 2024 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
24-09-11	52,500.00 ₩	+11.70%	3,039,719
24-09-10	47,000.00 ₩	+5.15%	578,946
24-09-09	44,700.00 ₩	+5.30%	393,272
24-09-06	42,450.00 ₩	-5.67%	413,477
24-09-05	45,000.00 ₩	-0.88%	554,918

End-of-day quote Korea S.E., September 10, 2024

More quotes

Income Statement and Estimates

More financial data

End-of-day quote Korea S.E. Other stock markets 2024-09-11			5-day change	1st Jan Change
52,500.00 ^KRW	+11.70%		+15.64%	+30.43%

2023	Invex Therapeutics, Peptron End Collaboration, Manufacturing Deal	MT
2023	Tranche Update on Peptron, Inc.'s Equity Buyback Plan announced on April 5, 2023.	CI

Capitalization	1,085B 811M 1.1B	P/E ratio 2022	-10.5x	P/E ratio 2023	-52x
Enterprise value	1,089B 814M 1.1B	EV / Sales 2022	25.8x	EV / Sales 2023	250x
Free-Float	90.19%	Yield 2022 *	-	Yield 2023	-

Invex Therapeutics, Peptron End Collaboration, Manufacturing Deal	12-21	MT
Tranche Update on Peptron, Inc.'s Equity Buyback Plan announced on April 5, 2023.	23-10-04	CI
Tranche Update on Peptron, Inc.'s Equity Buyback Plan announced on April 5, 2023.	23-10-04	CI
Peptron, Inc.'s Equity Buyback announced on April 5, 2023, has expired with 73,961 shares, representing 0.36% for KRW 891.08 million.	23-10-03	CI
Tranche Update on Peptron, Inc.'s Equity Buyback Plan announced on April 5, 2023.	23-07-07	CI
Peptron, Inc. announces an Equity Buyback for KRW 3,000 million worth of its shares.	23-04-05	CI
Peptron, Inc. authorizes a Buyback Plan.	23-04-04	CI
Peptron, Inc. Establishes Bioequivalence of PT105	22-11-27	CI
Invex Therapeutics Ltd Announces the Signing of a Long Term Collaboration and Manufacturing Agreement with Peptron, Inc	21-09-26	CI
Qilu Pharmaceutical and Peptron Sign License Agreement for Anti-MUC1 ADC	21-04-16	CI
Peptron, Inc. Announces Published Data Showing a New Sustained-Release Exendin-4 Formulation Prevents Neurodegeneration in a Parkinson's Disease Model	18-07-16	CI
Peptron, Inc. announced that it has received $24 million in funding	18-04-22	CI
Peptron, Inc. announced that it has received KRW 25.5 billion in funding from Industrial Bank of Korea	18-01-30	CI

1 day	+11.70%
1 week	+11.70%
Current month	+5.32%
1 month	-12.50%
3 months	+25.75%
6 months	+111.69%
Current year	+30.43%

Peptron, Inc. Stock

Equities

A087010

KR7087010005

Biotechnology & Medical Research

Valuation: Peptron, Inc.

Chart: Peptron, Inc.

Latest news: Peptron, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Peptron, Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Director	Title	Age	Since
Min-Ho Song CEO	Chief Executive Officer	63	21-03-29
Ho-Il Choi CEO	Chief Executive Officer	58	97-11-20
Seung-Gu Jang DFI	Director of Finance/CFO	58	99-06-30

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
PEPTRON, INC.	+11.70%	+11.70%	+32.08%	+323.39%	723M
REGENERON PHARMACEUTICALS, INC.	+0.45%	-3.22%	+36.94%	+78.49%	123B
VERTEX PHARMACEUTICALS INCORPORATED	+0.84%	-0.80%	+36.73%	+148.92%	122B
ARGENX SE	+0.74%	+5.29%	+1.46%	+76.27%	32.18B
BIONTECH SE	-1.35%	+11.51%	-15.84%	-69.66%	23.93B
BEIGENE, LTD.	+6.80%	+11.93%	+0.91%	-42.03%	21B
GENMAB A/S	-2.37%	-3.26%	-31.35%	-35.00%	17.38B
WUXI APPTEC CO., LTD.	+3.35%	+0.39%	-49.42%	-72.63%	14.82B
VAXCYTE, INC.	-2.31%	+4.03%	+116.62%	+327.04%	14.38B
SUMMIT THERAPEUTICS INC.	-1.18%	+89.17%	+1,292.64%	+259.75%	16.64B
Average	+2.28%	+12.08%	+142.08%	+99.45%	38.52B
Weighted average by Cap.	+0.93%	+3.98%	+79.48%	+91.38%

	2022	2023
Net sales	5.81B 4.35M 5.9M	3.34B 2.5M 3.39M
Net income	-15.06B -11.27M -15.29M	-15.92B -11.91M -16.16M
Net Debt	-8.02B -6M -8.14M	4.15B 3.1M 4.21M